Zacks: Analysts Anticipate Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Announce -$0.48 Earnings Per Share

Analysts forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) will post earnings of ($0.48) per share for the current quarter, Zacks reports. Two analysts have made estimates for Kiniksa Pharmaceuticals’ earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.50). Kiniksa Pharmaceuticals reported earnings per share of ($0.61) during the same quarter last year, which suggests a positive year over year growth rate of 21.3%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.05) to ($1.58). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($1.55) to ($1.25). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Rating) last released its earnings results on Tuesday, May 3rd. The company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.16. During the same quarter in the prior year, the company earned ($0.72) EPS.

Separately, Zacks Investment Research raised shares of Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Lazard Asset Management LLC bought a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $44,000. Macquarie Group Ltd. lifted its stake in Kiniksa Pharmaceuticals by 1,207.2% in the 3rd quarter. Macquarie Group Ltd. now owns 4,353 shares of the company’s stock worth $50,000 after purchasing an additional 4,020 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Kiniksa Pharmaceuticals by 424.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,633 shares of the company’s stock worth $64,000 after purchasing an additional 4,559 shares in the last quarter. Rockefeller Capital Management L.P. lifted its stake in Kiniksa Pharmaceuticals by 666.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 5,750 shares of the company’s stock worth $67,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Kiniksa Pharmaceuticals by 290.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,164 shares of the company’s stock worth $84,000 after purchasing an additional 5,327 shares in the last quarter. 42.57% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals stock opened at $9.89 on Monday. Kiniksa Pharmaceuticals has a twelve month low of $9.03 and a twelve month high of $16.68. The firm has a 50 day moving average price of $10.28 and a 200-day moving average price of $11.35. The company has a market capitalization of $683.44 million, a P/E ratio of -4.30 and a beta of 0.03.

Kiniksa Pharmaceuticals Company Profile (Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Stories